Biopharma Daily Stock Updates - 05/11/21

$CERC FDA grants Fast Track Designation to CERC-002 for hospitalized patients with COVID-19. source

$BNTX and $PFE EUA expanded for COVID-19 vaccine to include individuals 12 to 15 years of age. source

$NVAX PREVENT-19 Phase 3 COVID-19 trial protocol updated; final data expected in second quarter of 2021. source

$CLNN Phase 2 CNM-ZnAg COVID-19 trial initiated in Brazil. source

$PSTX Presents P-BCMA-ALL01 data at ASGCT 2021. source

$CDAK exoAAV gene therapy platform presented at ASGCT 2021 shows potential as novel, targeted approaches. source

$AXLA EMMPACT Phase 2b clinical trial of AXA1125 begins patient screening at initial clinical sites. source

$VYGR Novel adeno-associated virus capsids demonstrate robust delivery across blood brain barrier. source

$AGTC Manufacturing process for rAAV2tYF-GRK1-RPGRco presented at ASGCT. source

$LRMR Phase 1 topline data for CTI-1601 reported. source

$XLRN Will present updates to PULSAR and SPECTRA trials at ATS0 211 and webcast on 5/19/21. source

$BEAM LNP-mRNA formulation for liver editing presented at ASGCT. source

$ORTX OTL-101 data to treat ADA-SCID published in New England Journal of Medicine. source

$LVTX LAVA-051 will enter clinic in Phase 1/2a study in first half of 2021. source

$PMVP Will participate in Bank of America Healthcare Conference on May 13, 2021. source

$AUPH Company sponsored program initiated to help patients living with lupus and lupus nephritis. source

$MCRB Key data on C. Difficile infection therapeutics to be presented at DDW meeting May 21-23. source

$AVEO TIVO-3 Study data to be presented at ASCO meeting June 4-8. source

$DTIL In vivo genome editing program preclinical data presented at ASGCT. source

$MYOV Relugolix PDUFA dates still set for June 1 2021 and on track to submit regulatory filing for endometriosis in second quarter 2021. source

$APLT Phase 2 study of AT-007 in patients with SORD initiated. source

$IMRA IMR-687 Completed Phase 2a trial to present additional data at EHA June 9-17. source

$PCRX Preliminary net product sales of EXPAREL and iovera in April 2021 were $42.1M and $1.5M respectively. source

$RAPT Cast as of first quarter was $98.4M and increase in clinical costs caused R&D expenses to increast to $13.8M. source

$ADMS First quarter revenue of $19.3M, 33% increase from 2020. source